Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-05175157 Monotherapy in Type 2 Diabetes
NCT01792635Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Dec 2012
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PF-05175157 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Pfizer. Primary endpoints: Glucose Infusion Rates at 1 day, Endogenous Glucose Production at 1 day and 5 more. Started Dec 2012; status: terminated.
02
Drugs
PF-05175157
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01792635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01792635.